Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human …

Amgen’s medicines treat serious illnesses and typically address diseases with a limited number of treatment options. With a presence in approximately 100 countries, we are proud to have …

Making a positive difference in the world is at the heart of what we do at Amgen—and it goes beyond making vital medicines. Each year, Amgen and our staff members dedicate significant …

Media Relations For all media inquiries, please contact: [email protected] View key contacts for members of the media.

Amgen is committed to developing new therapies to treat serious illnesses—a long and careful process. One of the most important steps in this process is the clinical trial where people …

Through the Worldwide Compliance & Business Ethics Program, Amgen's leadership empowers managers and staff to conduct business ethically by providing resources such as the Code of …

View original content to download multimedia: http://www.prnewswire.com/news-releases/amgen-announces-positive-topline-phase-2-results-for-investigational-kras-g12c-inhibitor-sotorasib-in …

THOUSAND OAKS, Calif., Jan. 10, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Journal of the American Medical Association (JAMA) publication of findings …

THOUSAND OAKS, Calif., Feb. 2, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the FOURIER trial evaluating whether Repatha ® (evolocumab) reduces the …

Update on Change Healthcare CyberattackUpdate on Change Healthcare Cyberattack Change Healthcare, one of the country’s largest insurance claim processing clearinghouses, reported a …